Natera, Inc.
Financials
Valuation Metrics
Natera, Inc.'s Market Cap is $54.25B. At end of 2025 it was $31.32B. Ranked #281 of 3,118 in US market (top 9%), #78 of 1,474 on NASDAQ (top 5%), #15 of 203 in Health Care Equipment & Services (top 7%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $54.25B | US#281/3,118 Sec#15/203 |
| Revenue | $2.71B | US#1,250/3,118 Sec#77/203 |
| Net Income | $-192M | US—/3,118 Sec—/203 |
| Total Assets | $2.66B | US#1,891/3,118 Sec#92/203 |
| Net Assets | $1.82B | US#1,308/3,118 Sec#67/203 |
| Employees | 6,138 | US#1,106/3,118 Sec#83/203 |
| Value | ||
| P/B | 29.78x | US#2,857/3,118 Sec#188/203 |
| P/S | 20.04x | US#2,861/3,118 Sec#199/203 |
| FCF Yield | 0.13% | US#2,243/3,118 Sec#143/203 |
| Profitability | ||
| ROE | -10.56% | US#2,369/3,118 Sec#140/203 |
| ROA | -7.24% | US#2,591/3,118 Sec#150/203 |
| Op. Margin | -10.70% | US#2,518/3,118 Sec#159/203 |
| Revenue Growth | 37.82% | US#325/3,118 Sec#21/203 |
| Financial Health | ||
| Debt Ratio | 45.90% | US#522/3,118 Sec#56/203 |
| Total Debt | $238M | US#2,177/3,118 Sec#117/203 |
| FCF | $72M | US#1,846/3,118 Sec#112/203 |
| Cash | $1.09B | US#637/3,118 Sec#35/203 |
| Current Ratio | 3.00x | US#777/3,118 Sec#78/203 |
| Performance | ||
| 1Y Return | 90.43% | US#106/3,118 Sec#17/203 |
| 1M Return | -7.68% | US#1,755/3,118 Sec#133/203 |
| From 52W High | -13.39% | US#440/3,118 Sec#41/203 |
| 1Y MDD | -28.20% | US#1,174/3,118 Sec#52/203 |
| Trading | ||
| Volume | 2,360,961 shares | US#1,072/3,118 Sec#58/203 |
| Trading Value | $924M | US#158/3,118 Sec#9/203 |
| Per Share | ||
| EPS | $-1.34 | US—/3,118 Sec—/203 |
| BPS | $12.72 | US#1,658/3,118 Sec#93/203 |
Company Info
Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.